Abbott Laboratories has announced that it expects to complete its acquisition of Exact Sciences Corporation on March 23, 2026, following the receipt of all required regulatory approvals.
The acquisition marks a significant strategic move for Abbott, enabling the company to expand into high-growth segments of cancer screening and diagnostics. By integrating Exact Sciences’ capabilities, Abbott aims to accelerate innovation, broaden access to advanced diagnostic solutions, and support early detection and management of cancer for millions of patients worldwide.
Commenting on the development, Robert B. Ford, chairman and chief executive officer of Abbott, stated that the transaction aligns with the company’s long-term strategy of proactively evolving its portfolio to address future healthcare needs while driving sustained shareholder value. He noted that the addition of Exact Sciences enhances Abbott’s diagnostics leadership and introduces a strong platform in cancer screening, furthering its mission to improve accessibility and empower individuals to take control of their health.
Exact Sciences is widely recognized for its leadership in cancer screening, precision oncology, and genetic testing. Its portfolio includes innovative diagnostic solutions designed to detect cancer early, guide personalized treatment decisions, and monitor disease recurrence.
With this acquisition, Abbott strengthens its position in the diagnostics sector, particularly in the rapidly expanding field of oncology diagnostics. The move supports the company’s focus on advancing technologies that are preventive, predictive, and personalized, while expanding its footprint in a segment witnessing strong global demand due to rising cancer incidence.
Exact Sciences’ key products include Cologuard, a leading non-invasive colorectal cancer screening test; Oncotype DX, which helps inform treatment decisions for early-stage breast cancer patients; Oncodetect, a molecular residual disease (MRD) test designed to identify cancer recurrence; and Cancerguard, a multi-cancer early detection blood test. In addition, the company maintains a robust pipeline of next-generation diagnostics aimed at improving early detection, optimizing therapies, and enabling continuous disease monitoring.
Financially, the acquisition is expected to contribute approximately USD 3 billion in incremental sales in 2026. It is also projected to accelerate Abbott’s overall revenue growth by around 0.5 Percent, while resulting in a temporary dilution of approximately USD 0.20 in adjusted earnings per share for the year.
Abbott, a global healthcare leader, continues to build a diversified portfolio spanning diagnostics, medical devices, nutrition, and branded generics. The addition of Exact Sciences further reinforces its commitment to delivering innovative, life-changing technologies across the continuum of care.
